Previous 10 | Next 10 |
NORSE EIGHT clinical trial is being conducted under Special Protocol Assessment (SPA) from FDA to support expected resubmission of the ONS-5010 Biologics License Application (BLA) by the end of CY2024, if successful ISELIN, N.J., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, I...
2024-01-23 09:45:09 ET More on Outlook Therapeutics Outlook Therapeutics GAAP EPS of -$0.24 Outlook Therapeutics appoints new head of licensing and M&A Seeking Alpha’s Quant Rating on Outlook Therapeutics Historical earnings data for Outlook Therap...
Obtained clarity from U.S. Food and Drug Administration (FDA) on next steps to advance ONS-5010 NORSE EIGHT expected to commence in the first quarter of CY2024, enabling potential resubmission of the ONS-5010 Biologics License Application (BLA) by the end of CY2024 Private placements to t...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 investing in Outlook securities between December 29, 2022 and August 29, 2023 and wo...
SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a deadline is coming up in the lawsuit filed for certain investors in shares of Outlook Therapeutics, Inc. (NASDAQ: OTLK). Investors, who lost more than $200,000 with shares of Outlook Therapeutics, ...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 investing in Outlook securities between August 3, 2021 and August 29, 2023 and would...
Commencement of ONS-5010 NORSE EIGHT clinical trial targeted for first calendar quarter of 2024 Company reaffirms potential for European approval for ONS-5010 with Marketing Authorization Application (MAA) decision date anticipated in the first half of 2024 Resubmission of the ONS...
Philadelphia, Pennsylavnia--(Newsfile Corp. - December 20, 2023) - A securities fraud lawsuit has been filed against Outlook Therapeutics, Inc. ("Outlook") (NASDAQ: OTLK). The lawsuit is captioned Alsaidi v. Outlook Therapeutics, Inc. , No. 2:23-cv-21862 (D.N.J.), and is filed on behalf of purch...
NORSE EIGHT study on track to commence in Q1 2024 Resubmission of ONS-5010 Biologics License Application (BLA) in the U.S. expected by the end of calendar year 2024 ISELIN, N.J., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical c...
Murata Manufacturing Co. Ltd. ADR (MRAAY) is expected to report $0.27 for Q2 2024 Quotient Limited (QTNTQ) is expected to report for quarter end 2023-09-30 Evaxion Biotech A/S (EVAX) is expected to report for Q3 2023 American Virtual Cloud Technologies Inc. (AVCTQ) is expected to repo...
News, Short Squeeze, Breakout and More Instantly...
Outlook Therapeutics Inc. Company Name:
OTLK Stock Symbol:
NASDAQ Market:
Outlook Therapeutics Inc. Website:
2024-07-16 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UK MHRA marketing authorization follows recent European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) in the EU for the treatment of wet AMD Initial commercial launches of LYTENAVA™ (bevacizumab gamma) in the EU and UK anticipated in calendar Q1 2025...